acitretin has been researched along with Metabolic Syndrome in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Belinchón, I; Carrascosa, JM; Carretero, G; Dehesa, L; Ferrandiz, C; González-Quesada, A; Jorquera, E; Moreno, JC; Muñoz, C; Notario, J; Peral, F; Puig, L; Ribera, M; Vanaclocha, F; Vidal, D | 1 |
| Kirby, B; Ryan, C | 1 |
| Biterman, H; Cohen, AD; Feldhamer, I; Freud, T; Greenberg-Dotan, S; Harman-Boehm, I; Moser, H; Polishchuk, I; Shalom, G; Zisman, D | 1 |
| Berman, E; Cohen, AD; Eran, CB; Feldhamer, I; Freud, T; Hodak, E; Oren, S; Pavlovsky, L; Shalom, G; Ziv, M | 1 |
| Beutner, KR; Bhushan, R; Elmets, CA; Feldman, SR; Gordon, KB; Gottlieb, A; Koo, JY; Korman, NJ; Lebwohl, M; Leonardi, CL; Menter, A; Van Voorhees, AS | 1 |
1 review(s) available for acitretin and Metabolic Syndrome
| Article | Year |
|---|---|
Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities.
Topics: Acitretin; Adipokines; Alcoholism; Antibodies, Monoclonal, Humanized; Cardiovascular Diseases; Comorbidity; Cyclosporine; Dermatologic Agents; Diabetes Mellitus; Fumarates; Humans; Immunosuppressive Agents; Inflammation; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; Risk Factors; Smoking; Tumor Necrosis Factor-alpha; Ustekinumab | 2015 |
4 other study(ies) available for acitretin and Metabolic Syndrome
| Article | Year |
|---|---|
Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
Topics: Abnormalities, Drug-Induced; Acitretin; Biotransformation; Cardiovascular Diseases; Comorbidity; Contraindications; Drug Administration Schedule; Drug Interactions; Female; Gene Expression Regulation; Humans; Immunosuppressive Agents; Keratinocytes; Metabolic Syndrome; Pregnancy; Pregnancy Complications; Psoriasis; Receptors, Retinoic Acid; Risk Assessment; Tetracyclines | 2013 |
Factors associated with drug survival of methotrexate and acitretin in patients with psoriasis.
Topics: Acitretin; Administration, Oral; Adult; Age Factors; Aged; Arthritis, Psoriatic; Databases, Factual; Dermatologic Agents; Drug Prescriptions; Female; Folic Acid; Humans; Israel; Kaplan-Meier Estimate; Keratolytic Agents; Male; Medication Adherence; Metabolic Syndrome; Methotrexate; Middle Aged; Psoriasis | 2015 |
Biologic drug survival in Israeli psoriasis patients.
Topics: Acitretin; Adalimumab; Adult; Databases, Factual; Dermatologic Agents; Drug Substitution; Drug Therapy, Combination; Drug Tolerance; Etanercept; Female; Humans; Immunosuppressive Agents; Infliximab; Interleukin-12 Receptor beta 1 Subunit; Israel; Male; Metabolic Syndrome; Methotrexate; Middle Aged; Psoriasis; Time Factors; Tumor Necrosis Factor-alpha; Ustekinumab | 2017 |
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics.
Topics: Acitretin; Alefacept; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Arthritis, Psoriatic; Biological Products; Cardiovascular Diseases; Cyclosporine; Depression; Etanercept; Humans; Immunoglobulin G; Interleukin-12; Interleukin-23; Lymphoma; Metabolic Syndrome; Methotrexate; Obesity; Psoriasis; PUVA Therapy; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Smoking; Tumor Necrosis Factor-alpha | 2008 |